{"id":"bat5906-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAT5906 functions as a bispecific monoclonal antibody designed to target dual immune pathways, likely involving PD-1 and LAG-3 or similar checkpoint molecules. By blocking inhibitory signals on T cells through multiple mechanisms simultaneously, the drug aims to achieve greater immune activation and tumor control compared to single-checkpoint inhibitors.","oneSentence":"BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:03:35.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT04772105","phase":"PHASE1, PHASE2","title":"Clinical Study of the Safety and Efficacy of BAT5906 Injection","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-10-16","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT05141994","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of BAT5906 Injection","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-08-26","conditions":"Wet Age-related Macular Degeneration","enrollment":48},{"nctId":"NCT04151212","phase":"PHASE1","title":"A Phase I Clinical Trial of BAT5906 Injection in Patients With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2018-10-30","conditions":"Age-related Macular Degeneration","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["No Other Intervention Names"],"phase":"phase_3","status":"active","brandName":"BAT5906 injection","genericName":"BAT5906 injection","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAT5906 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}